Nick Thatcher
About
Nick Thatcher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Nick Thatcher has authored 117 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 28 papers in Molecular Biology. Recurrent topics in Nick Thatcher's work include Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (44 papers) and Colorectal Cancer Treatments and Studies (26 papers). Nick Thatcher is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (44 papers) and Colorectal Cancer Treatments and Studies (26 papers). Nick Thatcher collaborates with scholars based in United Kingdom, United States and Germany. Nick Thatcher's co-authors include Tudor–Eliade Ciuleanu, Alex Y. Chang, Purvish M. Parikh, Joachim von Pawel, José Rodrigues Pereira, Sumitra Thongprasert, Kristine Pemberton, Kevin Carroll, Venice Archer and E.H. Tan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
In The Last Decade
Nick Thatcher
116 papers receiving 5.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nick Thatcher United Kingdom | 34 | 4.0k | 3.9k | 1.5k | 810 | 434 | 117 | 5.7k | ||
| Petr Zatloukal Czechia | 33 | 3.7k 0.9× | 3.4k 0.9× | 1.6k 1.0× | 603 0.7× | 410 0.9× | 87 | 5.7k | ||
| Renato Martins United States | 20 | 4.6k 1.2× | 4.7k 1.2× | 1.7k 1.1× | 916 1.1× | 396 0.9× | 42 | 6.7k | ||
| Mircea Dediu Romania | 19 | 4.8k 1.2× | 5.1k 1.3× | 1.6k 1.1× | 894 1.1× | 267 0.6× | 55 | 6.6k | ||
| Aleksandra Szczęsna Poland | 23 | 4.4k 1.1× | 4.2k 1.1× | 1.2k 0.8× | 665 0.8× | 463 1.1× | 73 | 5.8k | ||
| Hiroshi Nokihara Japan | 40 | 3.9k 1.0× | 3.3k 0.8× | 1.7k 1.1× | 935 1.2× | 656 1.5× | 237 | 5.9k | ||
| Philip Bonomi United States | 42 | 4.9k 1.2× | 4.4k 1.1× | 2.1k 1.4× | 978 1.2× | 652 1.5× | 241 | 8.0k | ||
| Rogério Lilenbaum United States | 33 | 5.6k 1.4× | 5.5k 1.4× | 2.1k 1.4× | 1.2k 1.5× | 334 0.8× | 105 | 8.4k | ||
| Glenwood Goss Canada | 36 | 3.6k 0.9× | 3.5k 0.9× | 1.7k 1.1× | 865 1.1× | 299 0.7× | 129 | 6.3k | ||
| Masahiro Tabata Japan | 35 | 2.9k 0.7× | 2.9k 0.7× | 1.3k 0.8× | 606 0.7× | 465 1.1× | 225 | 4.5k | ||
| Radj Gervais France | 24 | 3.7k 0.9× | 4.0k 1.0× | 1.1k 0.7× | 617 0.8× | 246 0.6× | 83 | 5.2k |
Countries citing papers authored by Nick Thatcher
Since
Specialization
Citations
This map shows the geographic impact of Nick Thatcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Thatcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Thatcher more than expected).
Fields of papers citing papers by Nick Thatcher
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nick Thatcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Thatcher. The network helps show where Nick Thatcher may publish in the future.
Co-authorship network of co-authors of Nick Thatcher
This figure shows the co-authorship network connecting the top 25 collaborators of Nick Thatcher. A scholar is included among the top collaborators of Nick Thatcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Thatcher. Nick Thatcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Genova, Carlo, Mark A. Socinski, Rebecca R. Hozak, et al.. (2017). EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. Journal of Thoracic Oncology. 13(2). 228–236.
2.
Ciuleanu, Tudor–Eliade, Mark A. Socinski, Coleman K. Obasaju, et al.. (2015). Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study. Journal of Thoracic Oncology.
3.
Blackhall, Fiona, Mary O’Brien, Peter Schmid, et al.. (2010). A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(8). 1285–1288.
4.
Thatcher, Nick, Thomas J. Lynch, Charles Butts, et al.. (2009). Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials. Journal of Thoracic Oncology. 4(9).
5.
Amir, Eitan, Fiona Blackhall, Nick Thatcher, et al.. (2009). Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs. 18(11). 1667–1686.
6.
Gridelli, Cesare, Andrea Ardizzoni, Fortunato Ciardiello, et al.. (2008). Second-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 430–440.
7.
Booton, Richard, Tim Ward, Linda Ashcroft, et al.. (2007). ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2(10). 902–906.
8.
Gridelli, Cesare, Matti Aapro, Sandro Barni, et al.. (2007). Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel. Critical Reviews in Oncology/Hematology. 63(1). 53–64.
9.
Manegold, Christian, et al.. (2007). Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable Prognosis. Journal of Thoracic Oncology. 2(1). 51–58.
10.
Ferraldeschi, Roberta, Nick Thatcher, & Paul Lorigan. (2007). Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. Expert Review of Anticancer Therapy. 7(5). 635–640.
11.
Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855.
12.
Faivre‐Finn, Corinne, Paul Lorigan, Catharine West, & Nick Thatcher. (2005). Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. Clinical Lung Cancer. 7(1). 23–29.
13.
Lorigan, Paul, et al.. (2005). Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 97(9). 666–674.
14.
Thatcher, Nick, John R. Eckardt, & Mark A. Green. (2003). Options for first- and second-line therapy in small cell lung cancer — a workshop discussion. Lung Cancer. 41. S37–S41.
15.
Bleehen, N. M., D.J. Girling, David Machin, Richard Stephens, & Nick Thatcher. (1992). A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.. British Journal of Cancer.
16.
Thatcher, Nick, et al.. (1989). High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer. 63(7). 1296–1302.
17.
Wagstaff, John, et al.. (1982). The “Hot spleen” phenomenon in metastatic malignant melanoma. Its incidence and relationship with the immune system. Cancer. 49(3). 439–444.
18.
Thatcher, Nick, et al.. (1981). Effects ofCorynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days. Cancer. 47(2). 285–290.
19.
Thatcher, Nick, G. Blackledge, & Derek Crowther. (1980). Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrexate, and vitamin A. Cancer. 46(6). 1324–1328.
20.
Thatcher, Nick, R. Swindell, & Derek Crowther. (1979). Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.. PubMed Central. 35(2). 171–9.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Petr Zatloukal Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Glenwood Goss Breakdown of academic impact, for papers by Masahiro Tabata Breakdown of academic impact, for papers by Radj Gervais